Connect with us

Technology

How AI-Driven EHR Solutions from ModuleMD Are Transforming Specialty Practices

Published

on

GRAND BLANC, Mich., Nov. 25, 2024 /PRNewswire/ — As healthcare faces increasing demands for precision and efficiency, specialty practices like allergy, pulmonology, otolaryngology (ENT), and dermatology must adapt to remain competitive. ModuleMD is at the forefront of this transformation, integrating advanced AI technology into its Electronic Health Record (EHR) systems. By leveraging cutting-edge tools like SPOCK for front-office management, JOSH (Joint Operator for Supporting Healthcare) for AI-driven dictation, and InDrA for inventory management, ModuleMD is empowering specialty practices to streamline workflows, enhance patient care, and reduce costs. 

AI-Enhanced Decision Support 

ModuleMD’s AI algorithms deliver real-time, data-driven insights to guide diagnoses and treatment plans. For clinicians in specialties like allergy, JOSH acts as an AI-powered dictation assistant, transcribing patient encounters quickly and accurately. This allows providers to dedicate more time to patient care while minimizing documentation burdens. Research shows that AI-enhanced decision support can improve diagnostic accuracy by up to 20%, a critical advantage in specialties where timely, precise diagnoses are paramount. 

Streamlined Administrative Processes 

Administrative burdens can be a significant challenge for healthcare providers, but ModuleMD’s SPOCK simplifies these tasks. This AI-powered front-office solution automates processes, such as two-way texting, forms management, scheduling, patient communications, and prior authorizations. Allergy and pulmonology practices, in particular, benefit from these efficiencies, saving valuable time. Additionally, the Patient Cost Estimator tool offers real-time out-of-pocket cost estimates, boosting financial transparency and improving patient satisfaction by reducing surprise expenses. 

Reducing Billing Denials and Rejections 

Billing errors and claim rejections are persistent challenges for specialty practices, resulting in revenue loss and operational inefficiencies. ModuleMD’s AI-powered billing tools proactively identify potential issues before claims are submitted. By analyzing data and ensuring compliance with payer requirements, these tools flag discrepancies that could lead to denials. Otolaryngology (ENT) practices, for example, have seen significant improvements in claim acceptance rates. Practices using ModuleMD’s tools report up to a 40% reduction in claim denials, leading to better financial outcomes and allowing providers to focus on patient care. 

Personalized Patient Care 

With AI-driven insights, ModuleMD analyzes patient demographics and medical histories to enable personalized, proactive care. JOSH captures and documents patient information with precision, ensuring that treatment plans are tailored to individual needs. By automating data entry and facilitating seamless communication, JOSH allows clinicians to focus on delivering exceptional patient care with the support of informed, data-backed decisions. 

Ambient Listening and Clinical Note Preparation 

JOSH further revolutionizes clinical documentation through ambient listening technology. By capturing conversations between providers and patients in real time, JOSH generates accurate clinical notes during consultations. This feature is especially beneficial for high-volume practices like Otolaryngology (ENT), where maintaining detailed records is crucial. Ambient listening not only reduces documentation time but also ensures compliance and accuracy in medical records. 

Operational Efficiency Gains with InDrA 

Inventory management is a critical yet often overlooked aspect of specialty practices. InDrA, ModuleMD’s AI-powered inventory management system, optimizes stock levels by predicting supply needs based on usage trends. Allergy practices can manage allergen extracts, skin testing consumables, and other office supplies more efficiently, while dermatology and pulmonology practices can better handle costly medications and over-the-counter products. Practices using InDrA report up to a 30% reduction in inventory costs, leading to improved operational efficiency and profitability. 

Improved Diagnostic Accuracy 

ModuleMD’s platform includes AI-driven diagnostic tools, to enhance the precision of medical imaging and other diagnostic processes. For allergists, Vision AI analyzes skin test images, offering clinical grading with speed and accuracy. Similarly, in pulmonology and radiology, AI-powered imaging tools improve diagnostic accuracy by up to 87%, as validated in studies published in The Lancet. These tools reduce human errors, accelerating diagnosis and treatment. 

Enhanced Patient Engagement 

AI-powered chatbots and virtual assistants integrated into SPOCK streamline patient communication. These tools manage appointment reminders, follow-up queries, and routine interactions, fostering better engagement between providers and patients. Pulmonology practices, managing chronic conditions like COPD or asthma, benefit greatly from these AI tools, which improve treatment adherence and patient satisfaction. 

Immunotherapy Cost Estimator 

ModuleMD also provides the Immunotherapy Cost Estimator, a tool designed to assist allergy practices in predicting treatment costs. By offering precise estimates for patients and clinicians before treatments begin, this tool promotes transparent pricing and empowers practices to manage costs more effectively. This improves financial planning and builds patient trust. 

Transforming Specialty Practices with ModuleMD 

By integrating solutions like SPOCK, JOSH, InDrA, and the Immunotherapy Cost Estimator, ModuleMD empowers specialty practices to elevate clinical efficiency, improve patient care, and streamline operations. These AI-driven tools reduce administrative burdens, enhance diagnostic precision, and foster financial transparency, enabling specialty practices to thrive in today’s fast-paced healthcare environment. 

About ModuleMD 

ModuleMD, a leader in cloud-based healthcare management, has over 24 years of experience providing specialty-specific EHRs, practice management software, and patient engagement tools. Recognized as a G2 High Performer for four consecutive times, named among the Top 100 Healthcare Technology Companies of 2023 and listed as World’s Best Digital Health Companies 2024 on Newsweek.com. 

ModuleMD continues to innovate and equip healthcare providers with the best solutions for efficient, quality patient care. Stay updated with the latest from ModuleMD by following them on LinkedIn and YouTube.

Contact
cheryl.fernandes@modulemd.com 

Logo: https://mma.prnewswire.com/media/2314317/Module_MD_Logo.jpg

 

View original content:https://www.prnewswire.com/news-releases/how-ai-driven-ehr-solutions-from-modulemd-are-transforming-specialty-practices-302314049.html

SOURCE ModuleMD LLC

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Wistron Celebrates Grand Opening of First U.S. Smart Factory Marking Milestone in Global Smart Manufacturing Strategy

Published

on

By

FORT WORTH, Texas, July 21, 2026 /PRNewswire/ — Wistron Corporation (“Wistron”) celebrated the grand opening of its D1 AI smart facility in Fort Worth, Texas, the site where the first NVIDIA GB300 Grace Blackwell Ultra Superchip was built and mass-produced in the United States. The US$ 700 million facility, spanning approximately 324,000 square foot, was officially unveiled during a ceremony led by Wistron Chairman Simon Lin and NVIDIA Founder and CEO Jensen Huang. Jessica Rogers, Director of the Economic Development Department for the City of Fort Worth, and Alexander Tah-ray Yui, Taiwan’s Representative to the United States, were among the government officials and business leaders who attended, marking a milestone in the expansion of Wistron’s global footprint and advanced manufacturing capabilities.

This is a key hub in Wistron’s global AI infrastructure manufacturing network. The facility runs on NVIDIA accelerated computing and integrates NVIDIA’s Nemotron and Cosmos open frontier models and Omniverse and Metropolis libraries, using digital twin technology to optimize factory design, production workflows, and operational efficiency. It is Wistron’s first U.S.-based manufacturing facility, established to serve customers locally and produce NVIDIA’s most advanced and cutting-edge products. Wistron Chairman Simon Lin said “The operation here is not typical manufacturing. It is new, very comprehensive, and high-tech. Right now we produce the NVIDIA GB300 Grace Blackwell Ultra Superchip, and beyond, we are also going to produce the NVIDIA Vera Rubin Superchip here. In the next couple of years, this location will be one of the most important, as we build AI infrastructure here in the United States. I think this is the reason we say that there will be the next chapter, and we are going to empower AI from Texas.”

Responding to Customer Needs: Texas, the Newest Global Manufacturing Hub
At this pivotal moment for global AI infrastructure, Wistron is drawing on decades of global manufacturing experience to expand its footprint in Texas, a state with a well-established ecosystem for logistics, talent recruitment, and advanced manufacturing. The new D1 facility produces the NVIDIA GB300 Grace Blackwell Ultra Superchip and soon, the NVIDIA Vera Rubin Superchip — critical to powering the next generation of AI computing. The new Fort Worth facility strengthens a critical upstream layer of the AI infrastructure supply chain by expanding domestic capacity to assemble and test NVIDIA AI systems. These servers can be integrated into NVIDIA DSX infrastructure, with DSX providing the common architecture and technologies needed to deploy and operate energy-efficient AI factories at scale.

One-Stop Operational Ecosystem Strengthens U.S. AI Supply Chain Resilience
Behind every breakthrough in AI computing lies the manufacturing capability to scale it. Wistron is expanding its AI server production capabilities from Taiwan to the United States, guided by a vision of precision, efficiency, and sustainability. This reflects a broader industry shift: AI leadership is determined not only by technological breakthroughs, but also by the operational capability to transform innovation into high-volume production with consistent quality, supply chain resilience, and predictable delivery. By establishing AI infrastructure manufacturing capacity in the United States, Wistron is building a one-stop operational ecosystem spanning manufacturing and after-sales service — shortening delivery timelines and customer support cycles, strengthening supply chain resilience, and laying the foundation for long-term competitive advantage as AI infrastructure continues to scale.

Partnering with NVIDIA to Pioneer a New Model for Smart Manufacturing and Energy Optimization
As the era of physical AI begins, Wistron is extending its smart manufacturing capabilities to the United States, creating a new model for AI infrastructure production built on digital manufacturing, energy optimization, and local operations. Jensen Huang said: “The largest infrastructure buildout in history is underway. Demand for AI factories—the engine of this next industrial revolution—is incredible, and they must be produced everywhere. Together, NVIDIA and Wistron are restoring US advanced manufacturing capacity in Texas, creating skilled jobs and strengthening America’s AI supply chain.” As demand for advanced manufacturing grows in Texas, smarter planning of production loads and energy use will give the plant greater control and flexibility over its electricity needs.

Turning Global Experience into Scalable AI Infrastructure
Simon Lin stressed that the speed the AI era demands comes with its own responsibility. “In the AI era, the pressure of speed is also a form of responsibility,” Lin said. “We don’t just need to build fast; we need to build right.”

The Fort Worth plant will serve as the core engine of Wistron’s U.S. manufacturing operations, the company said, connecting its global production network with ecosystem partners as it scales advanced AI manufacturing. Wistron said that the investment reflects efforts to deepen its technical capabilities, strengthen the resilience and efficiency of global supply chains, and support the next phase of AI infrastructure development.

About Wistron:
Wistron Corporation is a leading global technology service provider delivering advanced ICT products, AI infrastructure, and manufacturing solutions to technology brands worldwide. With more than 63,000 employees across North America, Europe, and Asia, Wistron continues to expand its AI, cloud, and advanced manufacturing capabilities to support the next generation of intelligent computing. For more information about Wistron, please visit the official website at www.wistron.com. Additional information about the event is available on the event website.

Media Contact:
Joyce WL Chou
joyce_wl_chou@wistron.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/wistron-celebrates-grand-opening-of-first-us-smart-factory-marking-milestone-in-global-smart-manufacturing-strategy-302831439.html

SOURCE Wistron Corporation

Continue Reading

Technology

NSG Bio Accelerates Breakthrough Biotech Innovation in Singapore

Published

on

By

New initiative under NSG Bio Tomorrow will support promising startups developing next-generation approaches in respiratory and neonatal care

SINGAPORE, July 22, 2026 /PRNewswire/ — The NSG Bio Tomorrow initiative aims at supporting emerging life sciences startups working on complex challenges in respiratory and neonatal care.

Launched through the support of Chiesi Group, The Impulse initiative will provide a selected startup with one year of NSG Bio membership and access to a dedicated laboratory bench at NSG Bio Singapore. The initiative is designed to help early-stage biotech companies move from promising science toward stronger proof-of-concept work in a fully equipped research environment.

The initiative comes at a time when the biotech industry is increasingly looking for faster, more connected ways to move high-potential science from the lab toward real-world patient impact. For startups, access to infrastructure is only one part of the challenge. Equally important are the right networks, industry visibility, technical environment, and opportunities to engage with partners who understand the path from early discovery to clinical relevance.

The programme will focus on startups developing innovative biotechnological solutions with potential relevance to chronic respiratory diseases and neonatal conditions. Areas of interest include cell therapies, gene therapies, gene-editing technologies, regenerative tissue engineering, engineered or programmable living systems, lung-targeted delivery platforms, preventive approaches, and small-molecule-based approaches.

The selected startup will gain access to NSG Bio’s laboratory infrastructure, shared workspaces, meeting facilities, and wider community of biotech entrepreneurs, researchers, scientific leaders, and industry partners. The support is intended to help the company advance key research milestones while becoming part of Singapore’s growing life-science innovation ecosystem.

For NSG Bio, the initiative is part of NSG Bio Tomorrow, its ecosystem-building arm created to expand the company’s role beyond facilities and real estate. While NSG Bio is known for providing high-quality laboratory and office infrastructure for biotech companies, NSG Bio Tomorrow focuses on building the programmes, partnerships, and opportunities that help startups grow.

“Biotech companies need more than lab space. They need access, momentum, and the right ecosystem around them,” said Hasyim Sim, Co-Founder and Chief Operating Officer, NSG Bio. “Through NSG Bio Tomorrow, we are building initiatives that help promising startups connect with partners, unlock opportunities, and move their science forward. This initiative reflects exactly the kind of role we want to play in the biotech ecosystem.”

“Chiesi is committed to supporting innovation that can make a meaningful difference for patients, and we work with entrepreneurs, researchers and partners to advance meaningful ideas,” said Fabrizio Conicella, Vice President, Center of Open Innovation & Competence at Chiesi Group. “By supporting this NSG Bio Tomorrow initiative, we want to create an opportunity for early-stage innovators to access the infrastructure and ecosystem support needed to develop impactful science in respiratory and neonatal care.”

NSG Bio Tomorrow programme also reinforces Singapore’s position as a growing hub for biotech innovation in Asia, where startups, research institutions, investors, and industry partners are increasingly coming together to support the next generation of healthcare companies.

Applications open on 22 July 2026 at 09:00 a.m. SGT. Finalists will be invited to present at a virtual pitch event, after which the selected startup will be announced.

About NSG Bio

NSG Bio is Singapore’s leading provider of BSL-2 certified co-working laboratory and office spaces, supporting life-science companies from early research through growth. Through its facilities, community, and ecosystem initiatives, NSG Bio enables biotech innovators to accelerate research, access networks, and build companies that address critical healthcare challenges.

About NSG Bio Tomorrow

NSG Bio Tomorrow is NSG Bio’s ecosystem-building arm, created to support the next generation of biotech innovation through partnerships, programmes, community initiatives, and opportunities that extend beyond physical laboratory infrastructure. Its mission is to strengthen the biotech industry by connecting startups with the resources, expertise, and networks they need to thrive.

About Chiesi Group 

Chiesi is a research-oriented international biopharmaceutical group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. 

With 90 years of experience, Chiesi is headquartered in Parma (Italy), with 31 affiliates worldwide, and counts more than 7,900 employees. The Group’s research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden. For further information please visit https://www.chiesi.com/en/home 

Media Contact
Giridharan
Laboratory Manager
NSG Bio
giridharan@nsgbio.com
87797175

View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/nsg-bio-accelerates-breakthrough-biotech-innovation-in-singapore-302830494.html

SOURCE NSG Bio

Continue Reading

Technology

House Judiciary Committee Passes Bill that Would Prevent Future Immigration Crises: Swift Action Needed by Full House, Says FAIR

Published

on

By

WASHINGTON, July 21, 2026 /PRNewswire/ — Today, the House Judiciary Committee passed an updated version of H.R. 2, the landmark border security bill from last congressional session. The bill now awaits consideration by the full House of Representatives. The Federation for American Immigration Reform (FAIR) urges Speaker Mike Johnson to schedule a final floor vote as soon as possible.

The Secure Border Act systematically closes the loopholes that allowed the Biden administration to unleash the largest and most damaging wave of illegal immigration in American history. Enactment of this legislation would prevent future anti-borders administrations from shirking their responsibilities to secure our borders and enforce our immigration laws; asserting unlimited discretion to parole inadmissible aliens to enter the country; or releasing millions of illegal aliens into the country, rather than detaining them or returning them to the country from which they entered.

“We congratulate the Judiciary Committee for its swift action on this critical legislation,” said Dale Wilcox, executive director and general counsel of FAIR. “Ending border chaos and rampant illegal immigration was a key reason that Republicans regained control of the White House and both chambers of Congress in the last election. The clock is ticking on the 119th Congress, and Republicans only have a short time to deliver on the promises they made to voters in 2024, before the midterms.

“Right now, our immigration laws are being enforced in the interests of the American people. As the last administration demonstrated, enforcement of those laws is not guaranteed unless Congress acts to prevent similar abuse in the future. Now is the time for decisive action in the House, where this bill can be passed with a simple majority vote, and an opportunity for Senate Majority Leader John Thune to put every member of that body on record before voters go to the polls in the fall,” Wilcox concluded.

Hayley Hill, hhill@fairus.org 202-328-7004

View original content to download multimedia:https://www.prnewswire.com/news-releases/house-judiciary-committee-passes-bill-that-would-prevent-future-immigration-crises-swift-action-needed-by-full-house-says-fair-302831443.html

SOURCE Federation for American Immigration Reform (FAIR)

Continue Reading

Trending